TG-2349, A Potent Protease Inhibitor, plus PegIFN/Rbv Provides Excellent Virological Responses for Harder-to-Treat Subpopulations of HCV-1b non-Cirrhotic Patients

Ming-Lung Yu1, Shih-Jer Hsu2, Chau-Ting Yeh3, Chau-Hung Hwang4, Chih-Ling Lin5, Ming-Yao Chen6, Po-Chen Chen7, Chien-Chun Huang8, Pin-Nan Cheng9, Tsung-Hui Hu4, Chih-Ming Chen10. 1. Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC. 2. Department of Gastroenterology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC. 3. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC. 4. Department of Gastroenterology, Chang Gung Memorial Hospital, Taichung, Taiwan. 5. Department of Gastroenterology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. 6. Liver Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC. 7. Department of Gastroenterology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC. 8. Department of Gastroenterology, Chang Gung Memorial Hospital, Linkou, Taiwan, ROC. 9. Department of Gastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 10. TaiGen Biotechnology Co., Ltd., 138 Hsin Ming Rd., Taipei, Taiwan, ROC. 11. Tainan Medical Research Center, Tainan, Taiwan, ROC.